Resources

27
Apr

PRESS RELEASE – Genoskin appoints new board member to strengthen governance

Genoskin strengthens governance with appointment of industry leader Fabrice Bouteille, a strategic milestone reinforcing independence, global growth, and leadership in human-relevant research.

26
Mar

POSTER – SOT HypoSkin Pharma Latch

Home / Resources / Posters Poster Replacing animal testing in local tolerance assessment of an injection device: Human ex vivo HypoSkin® model as a New Approach Methodology (NAM) Jérémy Argenty1, Clémence Letzelter1, Catherine Marques1, Sophie Abadie1, Alexia Sanchez1, Claire Gendrin1, Alexandra Ochando1, Adam Rock2, Ronan Byrne2, Pascal Descargues1 and Nicky Bertollo2 1Genoskin, 2Pharma Latch HypoSkin® is an ex vivo human skin NAM that
Read more
26
Mar

POSTER – SOT Hyposkin argenx

Home / Resources / Posters Poster HypoSkin® as a human-based NAMs platform for local toxicity and formulation safety assessment Julie Magerman1, Katarzyna Polak2, Ornella Binazon1, Michael Pastore2, Alexandra Ochando2 and Judith Baumeister1 1argenx, 2Genoskin Local Toxicity and Formulation Safety: An argenx Collaboration Study Formulation safety testing still relies heavily on in vivo studies due to limited validated in vitro alternatives. Genoskin’s HypoSkin® biostabilized ex vivo human skin
Read more
18
Mar

PRESS RELEASE – Genoskin collaboration with argenx

At the 2026 annual meeting of the Society Of Toxicology (SOT), we will present new data demonstrating the value of our HypoSkin® ex vivo human skin platform as a translational human-based New Approach Methodology (NAM) for early safety assessment. The poster, developed in collaboration with argenx, will highlight how our platform can support early local tolerance screening and help reduce reliance on animal testing in formulation safety evaluation.

17
Feb

WEBINAR #15 – Preclinical evaluation of an energy-driven device for localized skin delivery of nucleic acids

Top-level science through the eyes of an expert.Preclinical evaluation of an energy-driven device for localized skin delivery of nucleic acidsDid you miss the live session? The full webinar recording is now available to watch on demand. Explore preclinical insights into an energy-driven, microneedle-based device enabling localized, non-viral delivery of naked nucleic acids to skin, highlighting transgene expression, immune activation, and
Read more
2
Feb

APPLICATION NOTE – NativeSkin® & UV testing

Explore how NativeSkin® supports ethical, human-relevant, and translational research in UV testing, phototoxicity assessment, and photobiology.